News brief­ing: Beam bags a $260M pri­vate place­ment; mi­Ra­gen re­brands to Virid­i­an Ther­a­peu­tics

Agios vet John Evans has demon­strat­ed how to raise big mon­ey for a lit­tle biotech.

The Beam Ther­a­peu­tics CEO — and ARCH part­ner — has pieced to­geth­er a $260 mil­lion pri­vate place­ment from a group of back­ers that in­cludes Per­cep­tive Ad­vi­sors, Far­al­lon Cap­i­tal, Cas­din Cap­i­tal, Red­mile Group and Cor­morant As­set Man­age­ment. And there are 3 main goals they’ll pur­sue with it: clin­i­cal de­vel­op­ment, strate­gic part­ner­ships and gen­er­al cor­po­rate pur­pos­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER